12-15 Molecular Diagnostics

East Haven, CT

Direct EB-5

Using its breakthrough Graphene Carbon-Nanotubes platform technology, Veralize, 12-15 Molecular Diagnostics has demonstrated its ability to detect at Point of Care (POC) virtually any pathogenic or carcinogenic material contained in many bodily fluids, e.g., saliva, blood, etc., with comparable sensitivity to RT-PCR — yet Veralize is substantively cheaper and faster than RT-PCR.

The company is now focused on early COVID-19 diagnosis. The National Institutes of Health (NIH) has recently ranked 12-15 Molecular Diagnostics in the top 5% of COVID-19 diagnostic companies and funded the construction of its beta prototypes earlier this year.

The company filed a pre-submission package with the U.S. Food and Drug Administration (FDA) in February 2021 and expects to be on the market by year end.